RenovoRx, Inc. (RNXT)

NCM – Real Time Price. Currency in USD

0.87

+0.02 (2.68%)

At close: May 12, 2026, 4:00 PM EDT

0.86

-0.01 (-0.95%)

After-hours: May 12, 2026, 7:22 PM EDT

07.05.2026

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

29.04.2026

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/.

23.04.2026

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

14.04.2026

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer

08.04.2026

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with 19 Issued or Allowed Patents and 14 Pending Patents Supporting the Commercialization of the RenovoCath Device MOUNTAIN VIEW, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

01.04.2026

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More

30.03.2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.

Videos

No Data

There is no data to display

Press releases

23.04.2026

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

14.04.2026

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer

08.04.2026

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

01.04.2026

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More

RenovoRx, Inc. (RNXT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Videos

No Data

Press releases

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Videos

No Data

Press releases

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Search stocks

RenovoRx, Inc. (RNXT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Videos

No Data

Press releases

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Videos

No Data

Press releases

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026